Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Phase 3

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Docetaxel
Radiation: radiotherapy
Drug: Cisplatin
Drug: Fluorouracil

First Posted Date: 2017-11-14

Last Posted Date: 2024-03-07

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 256

Registration Number: NCT03340896

Locations: 🇫🇷
Centre Jean Bernard, Le Mans, France

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: Carboplatin
Drug: Nivolumab
Drug: Placebo
Drug: Epacadostat
Drug: Cetuximab
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2017-11-14

Last Posted Date: 2019-12-20

Lead Sponsor: Incyte Corporation

Registration Number: NCT03342352

Modulated Electro-Hyperthermia Plus Chemo-radiation for Locally Advanced Cervical Cancer Patients in South Africa

Phase 3

Conditions: Cervical Cancer

Interventions: Device: Modulated electro-hyperthermia
Radiation: External beam radiation
Drug: Cisplatin
Radiation: Brachytherapy

First Posted Date: 2017-11-06

Last Posted Date: 2017-11-07

Lead Sponsor: Jeffrey Kotzen

Target Recruit Count: 236

Registration Number: NCT03332069

Locations: 🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Phase 1

Completed

Conditions: Diseases of Oesophagus Stomach and Duodenum

Interventions: Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Mitomycin C
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2017-11-06

Last Posted Date: 2023-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03330028

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Split Cisplatin
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2017-11-06

Last Posted Date: 2022-03-11

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 124

Registration Number: NCT03330249

Locations: 🇫🇷
Centre Paul Strauss, Strasbourg, France

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Neck
HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Interventions: Diagnostic Test: F-FMISO PET/CT Scan
Radiation: 30 Gy over 3 weeks
Drug: Cisplatin
Drug: Carboplatin
Drug: 5Fluorouracil
Radiation: Proton Therapy

First Posted Date: 2017-10-27

Last Posted Date: 2024-04-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 316

Registration Number: NCT03323463

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 7 locations

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Biliary Tract Cancer (BTC)
Colorectal Cancer (CRC)
Endometrial Cancer
Gastroesophageal Cancer (GC)
Ovarian Cancer
Solid Tumors

Interventions: Drug: INCB001158
Drug: Oxaliplatin
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Cisplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2017-10-19

Last Posted Date: 2023-12-07

Lead Sponsor: Incyte Corporation

Target Recruit Count: 149

Registration Number: NCT03314935

Locations: 🇺🇸
Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸
USA Mitchell Cancer Center, Mobile, Alabama, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 7 locations

Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Not Applicable

Active, not recruiting

Conditions: Esophageal Cancer

Interventions: Procedure: Esophagectomy
Drug: 5-fluorouracil
Drug: Cisplatin
Radiation: Radiation therapy

First Posted Date: 2017-10-11

Last Posted Date: 2024-05-23

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 240

Registration Number: NCT03306901

Locations: 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

and more 6 locations

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months

Phase 1

Completed

Conditions: Locally Advanced Cervical Cancer
Cervical Cancer

Interventions: Drug: Nivolumab Injection
Drug: Cisplatin
Radiation: radiotherapy

First Posted Date: 2017-10-02

Last Posted Date: 2024-02-02

Lead Sponsor: Institut Curie

Target Recruit Count: 21

Registration Number: NCT03298893

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut Curie Hopital René Huguenin, Saint Cloud, France
🇫🇷
Hopital Européen Georges Pompidou, Paris, France

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Phase 2

Completed

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2017-09-27

Last Posted Date: 2021-12-16

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 43

Registration Number: NCT03294304

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy